128 related articles for article (PubMed ID: 9516601)
41. 5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial.
Breul J; Jakse G; Forster G; Lampel A; Rohani A; Hartung R
Eur Urol; 1997; 32(3):280-3. PubMed ID: 9358213
[TBL] [Abstract][Full Text] [Related]
42. The French experience with infusional 5-fluorouracil in advanced colorectal cancer.
de Gramont A; Louvet C; Krulik M
J Infus Chemother; 1996; 6(3):133-6. PubMed ID: 9229324
[TBL] [Abstract][Full Text] [Related]
43. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
[TBL] [Abstract][Full Text] [Related]
44. Evolution in the treatment of advanced breast cancer.
Crown J
Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
[TBL] [Abstract][Full Text] [Related]
45. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
46. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
47. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
48. A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma.
Maiello E; Gebbia V; Giuliani F; Testa A; Giotta F; Gebbia N; Colucci G
Clin Ter; 1998; 149(5):351-5. PubMed ID: 10052247
[TBL] [Abstract][Full Text] [Related]
49. Clinical implications of 5-FU modulation.
Rustum YM
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):22-5. PubMed ID: 10442354
[TBL] [Abstract][Full Text] [Related]
50. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies.
Labianca R; Pessi A; Facendola G; Pirovano M; Luporini G
Eur J Cancer; 1996; 32A Suppl 5():S7-12. PubMed ID: 8958036
[TBL] [Abstract][Full Text] [Related]
51. [Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)].
de Gramont A; Louvet C; André T; Tournigand C; Raymond E; Molitor JL; Krulik M
Rev Med Interne; 1997; 18 Suppl 4():372s-378s. PubMed ID: 9365715
[TBL] [Abstract][Full Text] [Related]
52. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.
Pasquier E; Ciccolini J; Carre M; Giacometti S; Fanciullino R; Pouchy C; Montero MP; Serdjebi C; Kavallaris M; André N
Oncotarget; 2011 Oct; 2(10):797-809. PubMed ID: 22006582
[TBL] [Abstract][Full Text] [Related]
53. Relief of jaundice by 5-fluorouracil and folinic acid in patients with recurrent gastric cancer.
Kajiyama Y; Tsurumaru M; Udagawa H; Tsutsumi K; Kinoshita Y; Akiyama H
Surg Oncol; 1996 Aug; 5(4):177-81. PubMed ID: 9067566
[TBL] [Abstract][Full Text] [Related]
54. Expression of rTSbeta as a 5-fluorouracil resistance marker in patients with primary breast cancer.
Kuo SJ; Wang HC; Chow KC; Chiou SH; Chiang SF; Lin TY; Chiang IP; Chen DR
Oncol Rep; 2008 Apr; 19(4):881-8. PubMed ID: 18357371
[TBL] [Abstract][Full Text] [Related]
55. Leucovorin in combination chemotherapy of breast cancer.
Corder MP; Sheets RF; Stone WH; Flannery EP; Justice GR; Herbst KD
Clin Pharmacol Ther; 1977 Apr; 21(4):464-9. PubMed ID: 300314
[TBL] [Abstract][Full Text] [Related]
56. [5-fluorouracil and colorectal tumors: use in clinical practice and the "MISURA" project].
Labianca R; Poletti P
Tumori; 1998; 84(6 Suppl 2):S10-2. PubMed ID: 10083888
[TBL] [Abstract][Full Text] [Related]
57. 5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules.
Kamm YJ; Wagener DJ; Rietjens IM; Punt CJ
Anticancer Drugs; 1998 Jun; 9(5):371-80. PubMed ID: 9660532
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.
Cascino TL; Veeder MH; Buckner JC; O'Fallon JR; Wiesenfeld M; Levitt R; Goldberg RM; Kuross SA; Morton RF; Scheithauer BW
J Neurooncol; 1996 Dec; 30(3):243-6. PubMed ID: 8943099
[TBL] [Abstract][Full Text] [Related]
59. Management of locally advanced and disseminated breast cancer--chemotherapy.
Bisel HF
Cancer; 1980 Aug; 46(4 Suppl):1079-83. PubMed ID: 7397660
[TBL] [Abstract][Full Text] [Related]
60. [Evolving 5-Fluorouracil Therapy to Achieve Enhanced Efficacy-Past and Current Efforts of Researchers].
Maehara Y; Oki E; Saeki H; Tokunaga E; Kitao H; Iimori M; Niimi S; Kataoka Y; Emi Y; Kakeji Y; Baba H; Shirasaka T
Gan To Kagaku Ryoho; 2016 Jul; 43(7):845-54. PubMed ID: 27431628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
